Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048709 · ClinicalTrials.gov registry record · Phase 1
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02048709 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 22 participants.
The verdict
NCT02048709, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.
Interventions
- DRUG GDC-0919
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02048709
The ClinicalTrials.gov registry entry for NCT02048709 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-0919 is the first listed.
NCT02048709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02048709 about?
NCT02048709 is a clinical study titled "Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors". This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively...
What is the current status of trial NCT02048709?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2014-04. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02048709?
The interventions under investigation include: GDC-0919 (DRUG).
Who is sponsoring clinical trial NCT02048709?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.